))
Ep 14 | All About 340B Grantees (Part 2)
Manage episode 357160988 series 3374171
Content provided by SpendMend Pharmacy. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by SpendMend Pharmacy or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
This is part two of our two-part series focusing on 340B grantee-covered entities. The team talks about the importance of maintaining auditable records (15:34) and the challenges that many grantees face in meeting this 340B eligibility requirement. Also, they cover important billing considerations related to Medicaid Duplicate Discount prevention (31:20). Finally, the group debates future developments that 340B grantee-covered entities should keep on their radar through 2023 (45:52).
But first, Greg and Rob catch up on 340B implications from the Consolidated Appropriations Act of 2023 and share insights from a recent publication (J Manag Care Spec Pharm. 2023;29(3):229-35) that predicts which drugs will be subject to Medicare price negotiations starting in 2026 and beyond.
56 episodes
Share
